Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05827016 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,216
- Enrollment target
- 20
- Study locations
NCT05827016: Recruiting Phase 3 study of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
NCT05827016 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,216 participants, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05827016, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,216 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Iberdomide
Study Locations (20)
Florida
- Mayo Clinic Florida - Jacksonville
- Tampa General Hospital - Tampa
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
- Cleveland Clinic - Weston
Georgia
- University Cancer Blood Ctr - Athens
- The Winship Cancer Institute of Emory University - Atlanta
- Augusta University - Georgia Cancer Center - Augusta
Michigan
- University of Michigan - Rogel Cancer Center - Ann Arbor
- Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit - Detroit
- Cancer & Hematology Centers of Western Michigan (CHCWM) - Grand Rapids
New York
- Local Institution - 0328 - Brooklyn
- Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola - Mineola
Colorado
- Rocky Mountain Cancer Centers - Aurora
Illinois
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine - Chicago
Kansas
- University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion - Westwood
Maryland
- Maryland Oncology Hematology, PA- Clinton - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,216 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2036-01-01 |
| Phase | Phase 3 |
What NCT05827016 shows while recruiting
NCT05827016 is an interventional study that assigns participants to a tested intervention. Its 1,216 participants enrollment target places it among the larger protocols in the corpus, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (124% higher).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT05827016 names 20 study sites across 12 states, led by Florida, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT05827016 about?
NCT05827016 is a clinical study titled "A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
What is the current status of trial NCT05827016?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,216 participants. The study started on 2023-06-22. Estimated completion is 2036-01-01.
What conditions does trial NCT05827016 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05827016?
The interventions under investigation include: Lenalidomide (DRUG), Iberdomide (DRUG).
Who is sponsoring clinical trial NCT05827016?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05827016 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05827016's enrollment target sits among peer trials
1,216 19th of 438 higher than 420 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI